Bibliographic citations
Luna, C., (2024). Quimioterapia perioperatoria y adyuvante en la sobrevida de cáncer gástrico avanzado luego de gastrectomía más linfadenectomía D2 [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/27951
Luna, C., Quimioterapia perioperatoria y adyuvante en la sobrevida de cáncer gástrico avanzado luego de gastrectomía más linfadenectomía D2 [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/27951
@misc{renati/380869,
title = "Quimioterapia perioperatoria y adyuvante en la sobrevida de cáncer gástrico avanzado luego de gastrectomía más linfadenectomía D2",
author = "Luna Córdova, Cesia Jemima",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
Objective: To compare the effectiveness of perioperative chemotherapy with adjuvant chemotherapy in the survival of patients with gastric cancer after gastrectomy with D2 lymphadenectomy (T2-T4a). Materials and Methods: An observational, retrospective cohort study was performed on a census population matched by age and tumor location who had received perioperative or adjuvant chemotherapy in a Peruvian oncology institute between January 1, 2007 and December 31, 2022. To determine actuarial survival, the Kaplan-Meier method and the log-rank test for comparison of 2 survival curves will be used. A p value <0.05% will be considered statistically significant. Results: A total population of 82 patients was evaluated, of which 46 received adjuvant chemotherapy and 36 received perioperative chemotherapy, with CAPOX and EOX/EOX being the most commonly used regimens, respectively. Clinical characteristics did not significantly influence overall survival and only the primary tumor (T) had a statistically significant association, with T4a being more frequent in the perioperative chemotherapy group than in the adjuvant modality (80.6% vs 47.8%; p=0.002). When comparing both therapeutic modalities, it was evidenced that patients who received perioperative chemotherapy presented greater survival at 5 years (53.2%), however, this was not statistically significant (p=0.230). Conclusions: Perioperative chemotherapy presented greater survival compared to adjuvant chemotherapy at 12, 36 and 60 months; however, these differences were not statistically significant
This item is licensed under a Creative Commons License